Neurotrophic tyrosine kinase inhibitors: A review of implications for patients, clinicians and healthcare services

被引:4
|
作者
Walker, Andrew [1 ]
机构
[1] Calderdale & Huddersfield NHS Fdn Trust, Dept Pharm, Huddersfield, W Yorkshire, England
关键词
Neurotrophic tyrosine receptor kinase; larotrectinib; entrectinib; neurotrophic tyrosine receptor kinase inhibitor; oncology; ETV6-NTRK3 GENE FUSION; CANCER; TROPOMYOSIN; THERAPIES; PATHOLOGY; ONCOGENE; TRK;
D O I
10.1177/1078155220959428
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neurotrophic tyrosine receptor kinase (NTRK) inhibitors represent the latest advancement as a treatment option in targeted therapies for malignant disease. NTRK gene fusions involving NTRK1, 2 or 3 are implicated as genetics drivers for a number of tumour types which arise within adult and paedatric patients. NTRK inhibitors (Larotrectinib and Entrectinib) are effective agents which have demonstrated clinical benefit in the treatment of NTRK fusion positive solid tumours. Larotrectinib represents the first targeted agent to receive approval from international authorisation and commissioning bodies for the treatment of a specific genetic expression indiscriminate of the site from which the tumour has arisen. As such NTRK inhibitors could pave the way for international healthcare bodies to adopt a similar approach for future targeted therapies thereby altering the manner in which healthcare providers and patients are able to access and utilise innovative, targeted treatment options in future. The potential implications of this new approach are likely to impact upon several aspects of the traditional authorisation and commissioning pathways with potential changes to the design of clinical trials, the review and approval process by regulatory bodies and immunohistopathology services.
引用
收藏
页码:2015 / 2019
页数:5
相关论文
共 50 条
  • [1] The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer
    Passiglia, Francesco
    Caparica, Rafael
    Giovannetti, Elisa
    Giallombardo, Marco
    Listi, Angela
    Diana, Patrizia
    Cirrincione, Girolamo
    Caglevic, Christian
    Raez, Luis E.
    Russo, Antonio
    Rolfo, Christian
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (04) : 385 - 392
  • [2] Tyrosine kinase inhibitors in patients with neuroendocrine neoplasms: a systematic literature review
    Taboada, Rodrigo G.
    Cavalher, Felicia P.
    Rego, Juliana F.
    Riechelmann, Rachel P.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [3] Oral tyrosine kinase inhibitors in OMFS: a review
    Shah, P.
    Dylgjeri, F.
    Srinivasan, B.
    Brennan, P. A.
    BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2020, 58 (02): : 135 - 138
  • [4] Tyrosine kinase inhibitors in breast cancer (Review)
    Iancu, George
    Serban, Dragos
    Badiu, Cristinel Dumitru
    Tanasescu, Ciprian
    Tudosie, Mihai Silviu
    Tudor, Corneliu
    Costea, Daniel Ovidiu
    Zgura, Anca
    Iancu, Raluca
    Vasile, Danut
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 23 (02)
  • [5] Screening assays for tyrosine kinase inhibitors: A review
    Gao, Juan
    Jian, Jingyi
    Jiang, Zhengjin
    Van Schepdael, Ann
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2023, 223
  • [6] A Review on Newer Tyrosine Kinase Inhibitors and their Uses
    Kumar, Nithu M.
    Mathew, Meenu
    Anila, K. N.
    Priyanka, S.
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2018, 12 (08) : XE1 - XE6
  • [7] Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors
    Zhang, Kuojun
    Ye, Ke
    Tang, He
    Qi, Zhihao
    Wang, Tianyu
    Mao, Jie
    Zhang, Xiangyu
    Jiang, Sheng
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (07) : 4378 - 4416
  • [8] CLINICAL OUTCOMES OF PATIENTS WITH NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION CANCER TREATED WITH NON-TROPOMYOSIN RECEPTER KINASE INHIBITORS: A SYSTEMATIC LITERATURE REVIEW
    Pan, X.
    Jiao, X.
    Ruiz, K.
    Stewart, F.
    Kistler, K.
    Patel, R.
    Zong, J.
    Bernard-Gauthier, V
    VALUE IN HEALTH, 2022, 25 (12) : S50 - S50
  • [9] Corneal perforations in patients on tyrosine kinase inhibitors
    Amar, J.
    El Kaim, P.
    Scemla, B.
    Boumendil, J.
    Chotard, G.
    Gabison, E.
    Bouheraoua, N.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2023, 46 (09): : 1111 - 1113
  • [10] Bruton tyrosine kinase inhibitors for Waldenstrom macroglobulinemia: A review
    Moore, Donald C.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (08) : 1993 - 1999